®
Home
About
Capabilities
Products
Recent Launches
All Products
Product Catalog
Meitheal Product Catalog
Team
Customer Tools
Useful Links
Product Verification
Customer Service Information
Report an Adverse Drug Event
Return Goods Policy
ADR List
Anti-Capital Punishment Statement
News
All News
Latest News
Careers
Contact Us
Contact Us
News
Meitheal Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Cisatracurium Besylate Injection, USP 10mg per 5mL Due to Mislabeling
Jan 28 2021
Meitheal Pharmaceuticals Announces Launch of Enoxaparin Sodium Injection, USP in the United States
May 28 2020
CORONAVIRUS STATEMENT
Mar 24 2020
Meitheal Pharmaceuticals Announces FDA Approval of Additional Manufacturing Capacity and Future Facility Expansion Plans
for Production of Heparin Sodium Injection, USP
Feb 11 2020
Meitheal Pharmaceuticals Announces FDA Approval of Enoxaparin Sodium Injection, USP in the United States
Dec 05 2019
Meitheal Pharmaceuticals Announces Completion of Majority Stake Investment from Nanjing King-Friend Biochemical Pharmaceutical Company
Oct 31 2019
Meitheal Pharmaceuticals Announces Launch of Heparin Sodium Injection, USP in the United States
Sep 12 2019
Meitheal Pharmaceuticals Announces Investment from Nanjing King-friend Biochemical Pharmaceutical Company for Majority Stake
Aug 08 2019
Home
About Us
Capabilities
Products
Team
Careers
News
Contact Us
×
Email Us